Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status:
Recruiting
Trial end date:
2027-09-29
Target enrollment:
Participant gender:
Summary
The study will be conducted in 4 parts and will commence with dose escalation of AMX-500 as a
monotherapy (Part 1), followed by monotherapy dose expansion (Part 2).
- Part 1 (Monotherapy Dose Escalation): Single-agent AMX-500 dose escalation
- Part 2 (Monotherapy Dose Expansion): Single-agent AMX-500 dose expansion
The study may subsequently continue via a protocol amendment with dose escalation of AMX-500
combinations (Part 3) followed by combination therapy dose expansion (Part 4).